| Name | Title | Contact Details |
|---|
Vantage Health Plan is a Monroe, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As one of the largest and fastest-growing Emergency and Hospital Medicine groups in the nation, we partner with more than 5,000 world-class providers who treat more than 6 million patients annually. Physician-led, our team consists of motivated, personable, highly qualified people interested in putting the patient first. We’re committed to doing the right thing for the patients, physicians, and hospitals we serve. Which is why 98% of our physicians recommend us to colleagues and friends. William C. Schumacher, M.D., a board certified emergency medicine physician, formally founded the Schumacher Group in 1994. The philosophy behind Schumacher Group`s founding was based on his belief that there was a better way to deliver and manage emergency medical services in the hospital environment. That `better way` is embodied in our founding mission. The Schumacher Group became known as Schumacher Clinical Partners in 2016.
Island Gym & Fitness is a Absecon, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
THE SMITH AGENCY is a Marietta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.